Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ELVN
ENLIVEN THERAPEUTICS, INC.
NASDAQ
$57.86
▼ DOWN 4.36% (-2.64)

KEY STATISTICS

Market Cap$4.13 B
52w High$62.32
52w Low$14.79
Dividend Yield—
Frequency—
P/E-34.65
Volume584.96K
Shares Out.71.44M

COMPANY

LEADERSHIP

Richard A. Fair
CHIEF EXECUTIVE
Richard A. Fair

COMPENSATION 2026

Salary$561,190
Stock Awards$0
Incentive Plan Pay$302,500
All Other Comp.$2,719
Total$8,279,751

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 12, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
67

PRICE TARGET

Target High$82.00
Target Low$65.00
Target Median$78.00
Target Consensus$76.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2023-02-24Reverse1:4

PRICE

$57.86 ▼ DOWN 4.36% (−$2.64)
OVERLAYS
$58.00$59.00$60.00$61.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM57.86

About Enliven Therapeutics, Inc.

https://www.enliventherapeutics.com ↗

Enliven Therapeutics, a Boulder-based clinical-stage biopharma, develops small molecule kinase inhibitors like ELVN-001 and ELVN-002 for cancer treatment, currently in Phase 1 trials for leukemia and HER2-positive cancers.

INDUSTRY

Biotechnology

A PRODUCT ENLIVEN THERAPEUTICS, INC. IS KNOWN FOR

ELVN-001
ELVN-001

ELVN-001 is a potent, selective kinase inhibitor in clinical-stage development for CML, with positive Phase 1 data, and is Enliven's lead candidate advancing toward late-stage trials.

COMPETITORS

COMPETITOR
BMY COMPARE
COGT COMPARE
NVS COMPARE
PFE COMPARE
TAK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
136
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.3M
XSU.TO
0.08% · 1.1M
SCHA
0.07% · 258.2K
XPH
2.32% · 225.4K
DFAS
0.07% · 173.6K
PTH
1.71% · 79.7K
CANC
2.04% · 74.5K
FESM
0.06% · 69.5K
XRS2.DE
0.08% · 39.2K
NUSC
0.15% · 35.7K
RSSL
0.08% · 20.4K
BOUT
6.78% · 18.1K
BBSC
0.13% · 16.2K
AVSC
0.03% · 16.0K
WSCSRI.SW
0.11% · 14.5K
BBC
0.79% · 6.8K
PILL
1.56% · 6.3K
ACSG
0.33% · 2.8K
BIB
0.12% · 2.2K
RFLR
0.13% · 2.2K
RTWO.L
0.05% · 2.0K
ESSC
0.30% · 1.9K
BKSE
0.12% · 1.9K
TILT
0.00% · 1.7K
TNXT
0.15% · 456
RESM
0.13% · 135

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.22%
HOLDERS
251
TOP 12 OF 251 · RANKED BY POSITION SIZE
Fmr LLC
10.0M sh · $508.77M
Orbimed Advisors LLC
8.0M sh · $312.01M
Polar Capital Holdings Plc
6.4M sh · $326.35M
Commodore Capital LP
4.7M sh · $72.27M
Blackrock, Inc.
4.4M sh · $221.25M
Vestal Point Capital, LP
4.0M sh · $203M
Fairmount Funds Management LLC
3.7M sh · $57.16M
Vr Adviser, LLC
3.2M sh · $66.04M
Price T Rowe Associates Inc /Md/
2.9M sh · $147.37M
Vanguard Group Inc
2.8M sh · $43.15M
Blackrock Inc.
2.7M sh · $63.82M
Bellevue Group AG
2.3M sh · $90.98M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Collins Helen Louise
Purchase · 5.0K shares
2026-08-17
★
OFFICER: CHIEF FINANCIAL OFFICER
Hohl Benjamin
Sale · 4.6K shares
2026-08-17
★
OFFICER: CHIEF FINANCIAL OFFICER
Hohl Benjamin
Sale · 1.4K shares
2026-08-17
★
OFFICER: CHIEF MEDICAL OFFICER
Collins Helen Louise
Sale · 5.0K shares
2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 1
6 GRADES IN THE LAST 12 MONTHS
Mizuho OUTPERFORM Goldman Sachs BUY Guggenheim BUY Stifel BUY HC Wainwright & Co. BUY Jones Trading BUY

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
RLAY$18.77COMPARE
ATAI$7.29COMPARE
PGEN$6.95COMPARE
NKTR$72.52COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE
ORIC$13.24COMPARE